Neuropathic Pain – Pipeline Review, H2 2017
- Pages: 488
- Published: December 2017
- Report Code: GMDHC9966IDB
Global Markets Direct’s, ‘Neuropathic Pain – Pipeline Review, H2 2017’, provides an overview of the Neuropathic Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects
The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Neuropathic Pain
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
2-BBB Medicines BV
AbbVie Inc
Abide Therapeutics Inc
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Affectis Pharmaceuticals AG
AnaBios Corp
Anavex Life Sciences Corp
AngioChem Inc
Aptinyx Inc
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Aucta Pharmaceuticals LLC
BCI Pharma
BCN Peptides SA
Biogen Inc
Bionomics Ltd
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
Cara Therapeutics Inc
Celgene Corp
Centrexion Therapeutics Corp
Cerecor Inc
Chromocell Corp
Circuit Therapeutics Inc
Colby Pharmaceutical Co
ConSynance Therapeutics Inc
ContraVir Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Cytogel Pharma LLC
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Develco Pharma Schweiz AG
Dompe Farmaceutici SpA
Eisai Co Ltd
Eli Lilly and Co
Endece LLC
Evec Inc
Genecode AS
GL Pharm Tech Corp
Glialogix Inc
Grunenthal GmbH
GT Biopharma Inc
GW Pharmaceuticals Plc
Hydra Biosciences Inc
Immune Pharmaceuticals Inc
India Globalization Capital Inc
Intec Pharma Ltd
Integral Molecular Inc
IntelGenx Corp
Intellipharmaceutics International Inc
Ionis Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
JT Pharmaceuticals Inc
Knopp Biosciences LLC
Kolon Life Science Inc
KPI Therapeutics Inc
Lexicon Pharmaceuticals Inc
Lohocla Research Corp
Mapi Pharma Ltd
MD Biosciences GmbH
Medifron DBT Co Ltd
MEDRx Co Ltd
Medy-Tox Inc
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Mundipharma International Ltd
Nanomerics Ltd
Neurim Pharmaceuticals Ltd
Neurocentrx Pharma Ltd
NeuroCycle Therapeutics GmbH
NeurOp Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
Nippon Zoki Pharmaceutical Co Ltd
NoNO Inc
Novartis AG
Novassay SA
Orexigen Therapeutics Inc
Orion Corporation
Patagonia Pharmaceuticals LLC
PeriphaGen Inc
Pfizer Inc
Pharmaleads SA
Phosphagenics Ltd
RaQualia Pharma Inc
Re-Pharm Ltd
Relmada Therapeutics Inc
Revance Therapeutics Inc
Rottapharm Biotech Srl
Saniona AB
Scilex Pharmaceuticals Inc
Shionogi & Co Ltd
Sunovion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Theranexus SAS
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Trevena Inc
Vertex Pharmaceuticals Inc
Virobay Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.